Update date
12 Feb 2026
Shareable Research Card
SYRE - Spyre Therapeutics, Inc. Entity Common Stock, Shares Outstanding
This metric view shows SYRE - Spyre Therapeutics, Inc. entity common stock, shares outstanding history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2025
- Latest reported value
- 78,540,164
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 12 Feb 2026
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2025.
- Latest reported value on this page: 78,540,164.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Entity Common Stock, Shares Outstanding
Latest reported entity common stock, shares outstanding: 78,540,164. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 10 Apr 2026.
Benchmark Context
How Entity Common Stock, Shares Outstanding compares with peers
Spyre Therapeutics, Inc. is outside the visible top 120 companies for entity common stock, shares outstanding in the current sample.
Compared with
Compared with 120 companies reporting entity common stock, shares outstanding in shares. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0x the current sample midpoint. Entity Common Stock, Shares Outstanding does not yet have enough prior-period data for a historical comparison on this page.
- Visible rows currently span reported period ends from 28 Apr 2011 to 16 Apr 2026.
- Nearby companies in this sample: WORLD HEALTH ENERGY HOLDINGS, INC. and Healthier Choices Management Corp..
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Spyre Therapeutics, Inc.: Entity Common Stock, Shares Outstanding
Latest period: Q4 2025. Period end: 12 Feb 2026. Units: shares. Frequency: quarterly.
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Metric Snapshot
- Latest value
- 78,540,164
- Coverage range
- 08 Aug 2016 - 12 Feb 2026
- Fact rows
- 30
What This Metric Tells You
- Shows the reported level of entity common stock, shares outstanding over 08 Aug 2016 - 12 Feb 2026.
- Use consecutive periods in the table to assess trend direction when YoY change is unavailable.
- Built from 30 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Entity Common Stock, Shares Outstanding levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | WORLD HEALTH ENERGY HOLDINGS, INC. (when) | 550,834,347,495 | Instant - 19 Nov 2025 | Open WORLD HEALTH ENERGY HOLDINGS, INC. Entity Common Stock, Shares Outstanding |
| 2 | Healthier Choices Management Corp. (hcmc) | 527,156,418,606 | Instant - 27 Mar 2026 | Open Healthier Choices Management Corp. Entity Common Stock, Shares Outstanding |
| 3 | BANCO SANTANDER CHILE (bsac) | 188,446,126,794 | Instant - 31 Dec 2025 | Open BANCO SANTANDER CHILE Entity Common Stock, Shares Outstanding |
| 4 | BANK OF CHILE (bch) | 101,017,081,114 | Instant - 31 Dec 2024 | Open BANK OF CHILE Entity Common Stock, Shares Outstanding |
| 5 | Akari Therapeutics Plc (aktx) | 91,567,009,533 | Instant - 01 Mar 2026 | Open Akari Therapeutics Plc Entity Common Stock, Shares Outstanding |
| 6 | SatixFy Communications Ltd. | 85,672,474,000 | Instant - 31 Dec 2024 | Open SatixFy Communications Ltd. Entity Common Stock, Shares Outstanding |
Metric Details
- Metric
- Entity Common Stock, Shares Outstanding (EntityCommonStockSharesOutstanding)
- Taxonomy
- dei
- Units tracked
- shares
- Frequency coverage
- quarterly
- History range
- 08 Aug 2016 - 12 Feb 2026
- Facts on this page
- 30
- Description
- Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Change (%)
Spyre Therapeutics, Inc. Quarterly Entity Common Stock, Shares Outstanding (shares)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 78,540,164 | 12 Feb 2026 | 10-K | 19 Feb 2026 | 2025 | FY | ||
| Q3 2025 | 77,592,130 | +26,160,910 | +51% | 29 Oct 2025 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q2 2025 | 60,400,960 | +9,608,586 | +19% | 31 Jul 2025 | 10-Q | 05 Aug 2025 | 2025 | Q2 |
| Q1 2025 | 60,353,561 | +20,070,147 | +50% | 02 May 2025 | 10-Q | 08 May 2025 | 2025 | Q1 |
| Q3 2024 | 51,431,220 | +47,382,293 | +1170% | 01 Nov 2024 | 10-Q/A | 18 Nov 2024 | 2024 | Q3 |
| Q2 2024 | 50,792,374 | -50,400,547 | -50% | 01 Aug 2024 | 10-Q/A | 18 Nov 2024 | 2024 | Q2 |
| Q1 2024 | 40,283,414 | -25,111,745 | -38% | 01 May 2024 | 10-Q/A | 18 Nov 2024 | 2024 | Q1 |
| Q3 2023 | 4,048,927 | -57,462,151 | -93% | 03 Nov 2023 | 10-Q | 09 Nov 2023 | 2023 | Q3 |
| Q2 2023 | 101,192,921 | +40,020,411 | +65% | 04 Aug 2023 | 10-Q | 11 Aug 2023 | 2023 | Q2 |
| Q1 2023 | 65,395,159 | +14,975,337 | +30% | 02 May 2023 | 10-Q | 11 May 2023 | 2023 | Q1 |
| Q3 2022 | 61,511,078 | +12,191,120 | +25% | 28 Oct 2022 | 10-Q | 03 Nov 2022 | 2022 | Q3 |
| Q2 2022 | 61,172,510 | +12,107,952 | +25% | 29 Jul 2022 | 10-Q | 04 Aug 2022 | 2022 | Q2 |
| Q1 2022 | 50,419,822 | +2,403,930 | +5% | 28 Apr 2022 | 10-Q | 05 May 2022 | 2022 | Q1 |
| Q3 2021 | 49,319,958 | +1,382,851 | +2.9% | 28 Oct 2021 | 10-Q | 04 Nov 2021 | 2021 | Q3 |
| Q2 2021 | 49,064,558 | +4,464,711 | +10% | 30 Jul 2021 | 10-Q | 05 Aug 2021 | 2021 | Q2 |
| Q1 2021 | 48,015,892 | +3,422,128 | +7.7% | 12 Mar 2021 | 10-K | 18 Mar 2021 | 2020 | FY |
| Q3 2020 | 47,937,107 | +18,951,589 | +65% | 02 Nov 2020 | 10-Q | 05 Nov 2020 | 2020 | Q3 |
| Q2 2020 | 44,599,847 | +15,714,378 | +54% | 05 Aug 2020 | 10-Q | 10 Aug 2020 | 2020 | Q2 |
| Q1 2020 | 44,593,764 | +15,773,864 | +55% | 01 May 2020 | 10-Q | 07 May 2020 | 2020 | Q1 |
| Q3 2019 | 28,985,518 | +5,023,404 | +21% | 01 Nov 2019 | 10-Q | 06 Nov 2019 | 2019 | Q3 |
| Q2 2019 | 28,885,469 | +6,890,437 | +31% | 01 Aug 2019 | 10-Q | 06 Aug 2019 | 2019 | Q2 |
| Q1 2019 | 28,819,900 | +12,103,564 | +72% | 01 Mar 2019 | 10-K | 07 Mar 2019 | 2018 | FY |
| Q3 2018 | 23,962,114 | +7,317,791 | +44% | 02 Nov 2018 | 10-Q | 08 Nov 2018 | 2018 | Q3 |
| Q2 2018 | 21,995,032 | +5,542,772 | +34% | 03 Aug 2018 | 10-Q | 09 Aug 2018 | 2018 | Q2 |
| Q1 2018 | 16,716,336 | +3,264,076 | +24% | 08 Mar 2018 | 10-K | 13 Mar 2018 | 2017 | FY |
| Q3 2017 | 16,644,323 | +3,213,490 | +24% | 03 Nov 2017 | 10-Q | 07 Nov 2017 | 2017 | Q3 |
| Q2 2017 | 16,452,260 | +3,040,488 | +23% | 07 Aug 2017 | 10-Q | 09 Aug 2017 | 2017 | Q2 |
| Q1 2017 | 13,452,260 | 23 Mar 2017 | 10-K | 23 Mar 2017 | 2016 | FY | ||
| Q3 2016 | 13,430,833 | 09 Nov 2016 | 10-Q | 09 Nov 2016 | 2016 | Q3 | ||
| Q2 2016 | 13,411,772 | 08 Aug 2016 | 10-Q | 09 Aug 2016 | 2016 | Q2 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.